As the JP Morgan Conference virtually kicks off today, we announced a partnership with Sanofi to bring to market a next generation digital companion app for one of Sanofi’s most important treatments. BrightInsight has a long track record of partnering with innovative and forward-looking biopharma leaders including Novo Nordisk and CSL Behring, among others, and we are delighted to add Sanofi to the list.
Emmanuel Frenehard, Global Head of Digital at Sanofi, indicated that BrightInsight was selected to help Sanofi build and launch Sanofi’s latest Software as a Medical Device (SaMD), providing a disease management solution for one of its most important treatments. The partnership supports Sanofi’s digital strategy to create more engaging patient experiences with the goal to improve treatment outcomes.
Leveraging the BrightInsight® Platform, Sanofi’s digital companion application will provide easy access to patient services and support patients from therapy onboarding to chronic disease management with the aim to enhance patients’ healthcare experiences and outcomes. The solution includes a patient mobile app, which integrates with third-party systems for the creation of a connected ecosystem, and will enable users to manage their complex conditions with custom profile and content, and step-by-step therapy administration guidance. The app will be available first in the U.S. and then launch across international markets.
BrightInsight’s deep experience launching SaMD, regulatory expertise and robust platform enable us to support Sanofi’s goal of accelerating time to market in a manner that complies with the various critical and complex regulatory, quality, privacy and security requirements.
We are honored to partner with the Sanofi team as we work towards BrightInsight’s vision of transforming patient outcomes through digital.
I look forward to sharing more news as we head into a very busy 2022!